Characterisation of cellular defects in Niemann-Pick type C disease by Blom, Titta S.
  1
 
 
 
Characterisation of cellular defects in Niemann-Pick 
type C disease 
 
 
 
 
Titta S. Blom 
 
 
 
 
 
 
 
 
 
Department of Molecular Medicine 
National Public Health Institute, Helsinki 
and 
Department of Biosciences 
Division of Biochemistry 
Faculty of Science 
University of Helsinki 
Finland 
 
 
 
 
 
 
Academic Dissertation 
 
 
To be publicly discussed, with the permission of the Faculty of Science of the 
University of Helsinki, in the lecture room 2, Biomedicum Helsinki, on June 27th, 
2003, at 12 o’clock noon 
 
 
Helsinki 2003 
  2
 
Supervisor: 
Docent Elina Ikonen 
Department of Molecular Medicine 
National Public Health Institute 
Helsinki, Finland 
 
Reviewers: 
Professor Roger Morris 
MRC Centre for Developmental Neurobiology 
King’s College London, UK 
 
Docent Anu Jalanko 
Department of Molecular Medicine 
National Public Health Institute 
Helsinki, Finland 
 
Opponent: 
Professor Petri Kovanen 
Wihuri Research Institute 
Helsinki, Finland 
 
 
JULKAISIJA-UTGIVARE-PUBLISHER 
 
Kansanterveyslaitos (KTL) 
Mannerheimintie 166 
00300 Helsinki 
puh. 09-47441 
 
Folkhälsoinstitutet 
Mannerheimvägen 166 
00300 Helsingfors 
tel. 09-47441 
 
National Public Health Institute 
Mannerheimintie 166 
00300 Helsinki, Finland 
Phone +358 9 47441 
 
Publications of the National Public Health Institute 
KTL A11/2003 
ISBN 951-740-366-6 
ISSN 0359-3584 
ISBN 951-740-367-4 (PDF version) 
ISSN 1458-6290 (PDF version) 
 
Copyright National Public Health Institute 
 
Yliopistopaino 
  3
CONTENTS 
 
 
 
ORIGINAL PUBLICATIONS       5 
 
ABBREVIATIONS         6 
 
SUMMARY          8 
 
REVIEW OF THE LITERATURE      10 
 
1. Cholesterol in cellular membranes      10 
1.1 Detergent-resistant membrane domains    11 
1.2 Fatty acyl chain saturation     12 
 
2. Intracellular cholesterol homeostasis     13 
2.1 LDL receptor pathway      14 
2.2 De novo cholesterol biosynthesis and transport   14 
2.3 The SREBP pathway      15 
2.4 Cholesterol efflux       16 
 
3. Lysosomal lipidoses       16 
3.1 Accumulation of DRMs in lysosomal lipidoses   17 
 
4. Niemann-Pick type C disease      18 
4.1 Clinical characteristics of NPC     18 
4.2 Genetics of NPC       19 
4.3 Biochemical characterisation of NPC    20 
4.4 Diagnosis of NPC       22 
4.5 The structure and subcellular localisation of NPC1  22 
4.6 The structure of HE1/NPC2     26 
4.7 Regulation of cholesterol transport by NPC1   27 
 
AIMS OF THE STUDY        30 
 
METHODS          31 
 
RESULTS AND DISCUSSION       32 
 
1. Mass spectrometric analysis of lipids in normal and NPC cells (I) 32 
1.1 Lipid composition of control and NPC human fibroblasts 32 
1.2 Plasma membrane lipid composition in control and NPC cells 33 
1.3 The effect of acute cholesterol loading on cellular lipid  
composition        34 
 
2. The role of NPC1 in the recycling of LDL-cholesterol to the plasma  
membrane (II)         36 
2.1 Hydrolysis of [3H]CE-LDL in normal and NPC cells  36 
2.2 Association of cholesterol with DRMs    36 
  4
2.3 Association of NPC1 with DRMs    38 
2.4 Cholesterol efflux to extracellular acceptors   40 
2.5 Morphological characterisation of U18666A-treated cells 41 
 
3. Characterization of the trafficking defect in Finnish NPC cells (III) 41 
3.1 NPC1 mutation analysis      42 
3.2 Characterization of the NPC1 mutant protein in the patient  
fibroblasts        42 
3.3 Characterization of individual mutations using  
transient overexpression      43 
3.4 Functionality of the individual mutant proteins, as  
assessed by complementation assay     45 
3.5 NPC2 protein in control and NPC1 patient cells   46 
3.6 The population frequency and evolutionary conservation  
of the identified NPC1 mutations     47 
 
CONCLUSIONS AND FUTURE PROSPECTS     49 
 
ACKNOWLEDGEMENTS        51 
 
REFERENCES         52 
 
APPENDIX: ORIGINAL PUBLICATIONS I-III 
 
  5
ORIGINAL PUBLICATIONS 
 
This thesis is based on the following articles, which are referred to in the text by their 
Roman numerals. 
 
I  Blom TS*, Koivusalo M*, Kuismanen E, Kostiainen R, Somerharju P, Ikonen 
E. (2001). Mass spectrometric analysis reveals an increase in plasma 
membrane polyunsaturated phospholipid species upon cellular cholesterol 
loading. Biochemistry 40, 14635-14644.  
 
II  Lusa S*, Blom TS*, Eskelinen E-L, Kuismanen E, Mansson J-E, Simons K, 
Ikonen E. (2001). Depletion of rafts in late endocytic membranes is controlled 
by NPC1-dependent recycling of cholesterol to the plasma membrane. Journal 
of Cell Science 114, 1893-1900.  
 
III  Blom TS, Linder MD, Snow K, Pihko H, Hess MW, Jokitalo E, Veckman V, 
Syvänen A-C, and Ikonen E. (2003). Defective endocytic trafficking of NPC1 
and NPC2 underlying infantile Niemann-Pick type C disease. Human 
Molecular Genetics 12 (3), 257-272. 
 
*) Equal contribution. 
  6
ABBREVIATIONS 
ABCA1 ATP-binding cassette transporter A1 
ACAT acyl-CoA acyltransferase 
apoA-I apolipoprotein A-I 
CD cyclodextrin 
CE cholesterol ester 
CHO Chinese hamster ovary 
CSGE conformation sensitive gel electrophoresis 
7DHCR 7-dehydrocholesterol reductase 
DRM detergent-resistant membrane 
ECL enhanced chemiluminescence 
EEA-1 early endosomal antigen 1 
EM electron microscopy 
Endo H endoglycosidase H 
ER endoplasmic reticulum 
ERC endocytic recycling compartment 
GPI glycosyl phosphatidyl inositol 
HDL high-density lipoprotein 
HE1 human epididymis 1 
HMG-CoA 3-hydroxy-3-methylglutaryl-CoA 
INSIG insulin-induced gene 
kDa kilodalton 
LacCer lactocylceramide 
Lamp lysosome-associated membrane protein 
LBPA lysobisphosphatidic acid 
LDL low-density lipoprotein 
lgp lysosomal glycoprotein 
LPDS lipoprotein-deficient serum 
MPR mannose-6-phosphate receptor 
MVB multivesicular body 
NPA Niemann-Pick type A disease 
NPB Niemann-Pick type B disease 
NPC Niemann-Pick type C disease 
NPC1 Niemann-Pick protein 1 
NPC2 Niemann-Pick protein 2 
PC phosphatidylcholine 
PM plasma membrane 
PI phosphatidylinositol 
PS phosphatidylserine 
SCAP sterol regulatory element binding protein cleavage-activating protein
SCD stearoyl-CoA desaturase 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
  7
SM sphingomyelin 
SMase sphingomyelinase 
SRE sterol regulatory element 
SREBP sterol regulatory element-binding protein 
SSD sterol-sensing domain 
TX-100 Triton X-100 
VSV vesicular stomatitis virus 
wt wild type 
 
  8
SUMMARY 
 
Niemann-Pick type C disease (NPC) is a fatal recessively inherited neurological 
cholesterol-sphingolipidosis. The majority of the disease cases are caused by 
mutations in the NPC1 gene, the rest being caused by NPC2 mutations. The 
prominent cellular feature of NPC is the accumulation of free cholesterol within the 
late endosomes or lysosomes. In order to characterise the normal functions of the 
NPC proteins and the cellular defects in NPC, we used various different approaches. 
 
By mass spectrometry, we quantitatively determined the lipid molecular species in 
human control and NPC patient fibroblasts and in their plasma membrane 
incorporated into enveloped viruses (influenza and VSV). In viruses derived from 
NPC cells the cholesterol content was higher than in those from control cells. 
Glycolipids were enriched in domains through which influenza virus buds. Both the 
chronic cholesterol load (NPC cells) and the acute chemically induced load were 
accompanied by an increase in the polyunsaturated species of the major membrane 
phospholipids.  
 
The raft association of cholesterol and NPC1 protein was studied in normal and NPC 
cells. In normal cells, most of the of [3H]cholesterol released from [3H]cholesteryl 
ester-LDL associated with detergent-soluble membranes soon after its hydrolysis, and 
was rapidly transported to the plasma membrane, becoming increasingly detergent-
insoluble with time. In NPC cells, the raft association of LDL-derived cholesterol was 
enhanced compared to normal cells and its transport to the plasma membrane was 
inhibited, as measured by accessibility to cyclodextrin. In normal cells, the NPC1 
protein was mostly recovered in detergent-soluble membranes and its raft association 
was increased by late endosomal cholesterol loading. Our results thus suggest that late 
endocytic organelles are normally raft-poor, but in NPC there is overcrowding of raft 
lipids in the degradative compartments. In normal cells, endocytosed LDL-cholesterol 
is efficiently recycled to the plasma membrane in an NPC1-dependent process. 
 
We analysed the mutations causing a rapidly progressing infantile form of NPC. Two 
N-terminal point mutations (C113R, P237S) and a C-terminal four-nucleotide deletion 
leading to a frameshift and a premature stop codon (delC) in the NPC1 gene were 
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identified. When the mutations were individually expressed in cells, the delC was 
observed to produce an unstable protein. NPC1-wt and NPC1-P237S were localised to 
late endosomes, but NPC1-C113R mislocalised to the ER, cell surface and Rab7-
negative endosomes. NPC1-P237S, like NPC1-wt, was able to clear the late 
endosomal cholesterol accumulations from NPC cells, whereas NPC1-C113R and 
delC were unable to do this. When the frequencies of the mutations in the Finnish and 
Swedish populations were studied, P237S was observed as a prevalent NPC1 
polymorphism in the Finnish and Swedish populations. NPC2 protein was found to be 
upregulated in NPC1 patient cells and seen to accumulate in the cholesterol storing 
late endosomes. This suggests that NPC1 governs the endocytic transport of NPC2. 
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REVIEW OF THE LITERATURE 
 
1. Cholesterol in cellular membranes 
 
Cholesterol is an essential structural and regulatory component of cells and 
organisms. It is the major steroid constituent of animal tissues. Over past decades, this 
lipid has been intensively studied and many important findings related to its functions 
have been made (Vance and Van den Bosch, 2000). Cholesterol is the precursor for 
steroid hormones and bile acids and is also an important structural lipid in membranes 
(Tabas, 2002). The role of cholesterol in signalling has also become evident in recent 
years (Nybakken and Perrimon, 2002). Excessive amounts of cholesterol are toxic to 
cells and thus the cholesterol content of membranes has to be tightly regulated. The 
correct intracellular distribution of cholesterol is also crucial for the proper 
functioning of organisms. 
Membranes consist of lipid bilayers, which have various proteins associated 
either peripherally or integrated into the lipid bilayer (transmembrane proteins). In 
eucaryotes, the major lipid classes, in addition to cholesterol, are 
glycerophospholipids and sphingolipids. Lipids are asymmetrically distributed in 
cellular membranes. Phosphatidylcholine (PC), and the sphingolipids, including 
sphingomyelin (SM) and the important families of glycosphingolipids (notably the 
cerebrosides and gangliosides), are mainly located on the outer leaflet. The cytosolic 
leaflet is mainly composed of phosphatidylethanolamine (PE), phosphatidylserine 
(PS), and minor amounts of PC, phosphatidylinositol (PI) and other lipids (Voelker, 
2002). 
Lipids also have distinct intracellular distributions between membranes of 
subcellular organelles. The cholesterol concentration in the endoplasmic reticulum 
(ER), where it is synthesized is low, but the level increases from the cis- to the trans-
Golgi apparatus. Compared to other cellular membranes, the plasma membrane (PM) 
is highly enriched in cholesterol (Maxfield and Wustner, 2002). The endocytic 
recycling compartment (ERC) is also thought to be high in cholesterol (Hao et al., 
2002), whereas in normal conditions, the cholesterol concentration of late endosomes 
and lysosomes seems to be lower than that in the ERC (Hao et al., 2002; Liscum and 
Munn, 1999). Also, the SM concentration is thought to be relatively low in the ER 
and to increase on the way from the Golgi to the PM (van Meer, 1998). PC is thought 
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to be widely spread throughout the cellular membranes and is the most abundant 
phospholipid in the cells (Voelker, 2002). 
 
1.1 Detergent-resistant membrane domains  
Lipids are not homogeneously distributed in cellular membranes. Membrane rafts are 
lateral microdomains that are thought to consist of cholesterol and sphingolipids. The 
rafts seem to have a dynamic nature and are thought to be involved in several specific 
functions, such as membrane trafficking and sorting, cell polarization, and cell 
signalling. In mammalian membranes, rafts are thought to form a separate liquid-
ordered phase in the more loosely packed liquid-disordered phase (Brown and 
London, 1998; Simons and Ikonen, 1997). In raft membranes, SM, glycosphingolipids 
and cholesterol are thought to be located in the outer leaflet connected with 
phospholipids and cholesterol in the cytoplasmic leaflet (Fig. 1) (Simons and Ikonen, 
1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Model of lipid raft. The outer leaflet of the raft is enriched in glycosphingolipids and 
sphingomyelin, and the corresponding inner leaflet is illustrated as containing glycerolipids with 
predominantly saturated fatty acyl chains. Lipids within the liquid-ordered phase are shown with dark 
grey head groups and in the liquid-disordered phase with light gray head groups. Cholesterol, darkest 
grey, partitions preferentially into the liquid-ordered phase. A GPI-anchored protein is attached to the 
exoplasmic leaflet, and a signalling molecule Src-kinase to the cytoplasmic leaflet.  
 
GPI-
anchored
protein
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Natural sphingolipids have long and more saturated acyl chains than most 
glycerophospholipids (Edidin, 2003). This allows them to pack tightly together and is 
an important feature of raft lipid organisation. Cholesterol condenses the packing of 
sphingolipid molecules by occupying the spaces between the saturated hydrocarbon 
chains (Anderson and Jacobson, 2002). Also, the glycerophospholipids in rafts are 
thought to have more highly saturated fatty acyl chains that those in the surrounding 
membrane. The structure of the rafts may be further stabilised by intermolecular 
hydrogen bonds between the 3’-OH group of the sterol and the amide function of the 
sphingolipid ceramide backbone (Brown and London, 2000; Simons and Ikonen, 
2000). 
Rafts are also called detergent-resistant membranes (DRMs), because they 
have been studied and isolated on the basis of their resistance to non-ionic detergents 
such as Triton X-100 (TX-100) at low temperatures. Recently, a variety of other 
detergents have also been used to isolate DRMs, such as CHAPS, Lubrol, Brij 98, 
NP-40, and octylglucoside (Pike, 2003). The choice of detergent seems to affect the 
properties of the membrane fraction isolated (Drevot et al., 2002; Ilangumaran et al., 
1999; Roper et al., 2000). The precise raft lipid composition is not yet known in detail 
nor are the biophysical parameters controlling the microdomain assembly. In 
mammalian cells, rafts are thought to form in the Golgi apparatus, where sphingolipid 
synthesis takes place (Brown and London, 1998). There are several estimates of the 
microdomain size; in conclusion from several studies, the average diameter might be 
between 50-200 nm, well below the resolution of the light microscope (Pralle et al., 
2000; Schutz et al., 2000; Varma and Mayor, 1998). Several proteins resident in the 
raft microdomains are modified with lipid anchors such as 
glycosylphosphatidylinositol (GPI), palmitate or myristate chains. For transmembrane 
proteins, it has been suggested that the properties of the transmembrane domain, 
especially in the exoplasmic half, are critical for targeting to rafts (Scheiffele et al., 
1997). 
 
1.2 Fatty acyl chain saturation 
The composition of lipid bilayers is tightly controlled to maintain and regulate 
membrane fluidity. This regulation has an important physiological role and changes in 
normal membrane composition may lead to pathological states (Ntambi, 1999). In 
addition to cholesterol, which is crucial for membrane properties, lipid fatty acyl 
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chain length and saturation degree also regulate membrane fluidity (Cook and 
McMaster, 2002). Fatty acids are carboxylic acids with long-chain hydrocarbon side 
groups. In cells they seldom exist in free form but are usually attached to various 
lipids via ester bonds. Most lipids in eucaryotic membranes have fatty acyl chains 
with an even number of carbon atoms, the most common chain lengths being 16 or 18 
carbon atoms. In natural membranes, over half of the fatty acyl chains in lipids 
contain one or more double bonds and are thus referred to as mono-, di-, or 
polyunsaturated. Many of the unsaturated fatty acids are synthesised by mammalian 
cells, but there is a group of essential fatty acids that can only be obtained from 
dietary fats. By increasing the fatty acyl chain length, the membrane can be made 
more rigid. By introducing cis-double bonds in the hydrocarbon chain, the fluidity of 
the lipid molecule is increased, because this causes a sharp bend in the structure of the 
molecule and impairs the packing of the lipids in the membrane (Cook and McMaster, 
2002). A key enzyme in the synthesis of monounsaturated fatty acids from saturated 
ones is stearoyl-CoA desaturase (SCD) (Ntambi, 1999). 
 
2. Intracellular cholesterol homeostasis 
 
Cells have evolved several ways to regulate their cholesterol content by 
transcriptional, translational and post-translational mechanisms. Cholesterol can either 
be synthesised by the mammalian cells or taken from lipoproteins in the circulation. 
Free cholesterol can also be effluxed from the cells (Tall et al., 2002) or can be 
esterified in the ER by an enzyme acyl-CoA acyltransferase (ACAT) (Buhman et al., 
2001) and stored in cytoplasmic lipid droplets (Fig. 2). The synthesis and utilisation 
of cholesterol must be tightly controlled. Failure of these homeostatic responses leads 
to various diseases. Excess dietary cholesterol can cause one of the most common 
diseases to date, atherosclerosis (Libby et al., 2000). Cholesterol is essential for 
normal development; defects in its synthesis can lead to various malformation 
syndromes (Porter, 2002). Impaired intracellular cholesterol transport can cause 
pathological states such as Tangier disease, where the ATP-binding cassette 
transporter A1 (ABCA1) protein functioning in cholesterol efflux is defective (Oram, 
2002) and Niemann-Pick type C disease (NPC), where defects in intracellular 
cholesterol transport lead to endosomal cholesterol accumulation (Paterson, 2001).  
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2.1 LDL receptor pathway 
In the circulation, cholesterol is transported mainly in low-density lipoprotein (LDL) 
particles. The core of the particle is composed of cholesterol esters and triglycerides 
and the surface of free cholesterol, phospholipids and apolipoprotein B-100. LDL 
binds to the cell surface LDL receptors and is internalised through coated pits and 
coated vesicles by receptor-mediated endocytosis (Fig. 2). The clathrin coat of the 
vesicle is rapidly degraded and receptor-LDL complexes are delivered first to early 
and then to late endosomes, where LDL dissociates from its receptors owing to the 
acidic environment (Brown and Goldstein, 1986). LDL receptors are recycled back to 
the plasma membrane, while cholesterol esters are hydrolysed in the late endosomes 
and free cholesterol is transported to the ER and the PM by mechanisms as yet 
unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Compartmentalisation of cholesterol metabolism in the cell 
 
 
2.2 De novo cholesterol biosynthesis and transport 
Cholesterol is a planar four-ring structure composed of 27 carbon atoms with 
hydroxyl functional group attached to carbon 3 in -configuration. The biosynthesis 
of cholesterol takes place in the ER from acetyl-CoA. The rate limiting enzyme which 
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catalyses the step from HMG-CoA to mevalonate is 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) reductase. This reaction is followed by several steps catalysed by over 
30 enzymes leading to the final product, cholesterol (Liscum, 2002). Newly 
synthesised cholesterol is transported to the PM and to other cellular organelles by 
partly unknown mechanisms. Cholesterol transport seems to be energy-dependent, 
since it requires ATP (DeGrella and Simoni, 1982). A fraction of newly synthesised 
cholesterol is transported to the PM by a vesicle-mediated secretory pathway and is 
dependent on an intact microtubule network (Heino et al., 2000). Recent data suggest 
that the actin cytoskeleton and endocytic circuits also play important roles in the 
delivery of newly synthesised cholesterol to extracellular acceptors (S. Lusa and S. 
Heino, personal communication). 
 
2.3 The SREBP pathway 
A constant level of free cholesterol in the body is maintained by controlling several 
functions such as de novo synthesis, lipoprotein uptake, and cholesterol esterification 
and efflux. In mammalian cells, a well-studied machinery controls the genes involved 
in sterol homeostasis. The promoters of the sterol-regulated genes contain a sequence 
known as the sterol regulatory element (SRE). In mammalian cells, transcription 
factors called sterol regulatory element-binding proteins (SREBP) bind to these 
elements (Brown and Goldstein, 1999) and regulate over 20 genes that are involved in 
cholesterol homeostasis and in the synthesis of unsaturated fatty acids (Goldstein et 
al., 2002). The sterol regulatory element binding protein cleavage-activating protein 
(SCAP) senses the sterol content of the ER. In sterol-depleted cells, SCAP undergoes 
a conformational change leading to the transport of SREBP-SCAP complex to the 
Golgi where SREBP is proteolytically cleaved by two proteases, site-1 protease (S1P) 
and site-2 protease (S2P), and is released from the membranes. The cleaved, active N-
terminal domain of SREBP enters the nucleus, where it activates the transcription of 
sterol-regulated genes. When the sterol levels in the cells are high, the conformation 
of SCAP allows the SCAP-SREBP complex to associate with INSIG retention 
proteins and remain in the ER (Janowski, 2002; Yabe et al., 2002; Yang et al., 2002). 
As a consequence, the transcription of sterol-regulated genes is down-regulated. 
Recently HMG-CoA reductase levels in the cells have also been shown to be 
regulated by the INSIG-1 protein (Sever et al., 2003). 
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2.4 Cholesterol efflux 
Efflux from cells to extracellular acceptors is the first step in the process of reverse 
cholesterol transport, by which cholesterol is transferred from peripheral tissues to the 
liver for disposal. Passive aqueous diffusion and Scavenger receptor B-I (SR-BI) 
facilitated diffusion are bi-directional processes that involve the exchange of 
cholesterol between cells and high density lipoprotein (HDL) (Fielding and Fielding, 
2001; Tall et al., 2002). ABCA1-mediated cholesterol efflux is unidirectional to the 
apolipoprotein A-I (apo A-1) acceptor. Mutations in ABCA1 lead to Tangier disease, 
which is a severe HDL deficiency syndrome characterised by accumulation of 
cholesterol in tissue macrophages and prevalent atherosclerosis (Oram, 2002). Late 
endosomes and lysosomes have been suggested to act as preferential sources of 
cholesterol for ABCA1-mediated efflux (Chen et al., 2001). ABCA1 has been shown 
to rapidly recycle between the PM and the late endosomal compartments (Neufeld et 
al., 2001). However, it is not certain whether this recycling regulates the degradation 
of ABCA1 or the cholesterol efflux itself (Wang and Oram, 2002). 
 
3. Lysosomal lipidoses  
 
Lysosomal storage disorders are a group of over 40 genetic diseases that are typically 
caused by deficiency of a particular lysosomal protein. The disease phenotypes are 
often very broad, suggesting disturbances in the enzymatic cascades leading to the 
degradation of lysosomal substrates or impairment of the whole membrane trafficking 
system. The lysosomal storage diseases can be classified, depending on the nature of 
the accumulating substrate. In lysosomal lipidoses, different lipids accumulate in 
lysosomes owing to mutations mostly in lysosomal hydrolases but also in transport 
proteins and cause great variability of symptoms, which often include neuronal 
degeneration. For their degradation, some glycosphingolipids in lysosomes require 
helper proteins termed sphingolipid activator proteins, saposins (Gieselmann, 1995; 
Pagano et al., 2000). Mutations in these cofactors may also lead to decreased 
enzymatic activity and lysosomal lipidoses (Merrill and Sandhoff, 2002). 
Niemann-Pick diseases are a group of clinically similar lysosomal lipidoses 
that have been divided into three different subtypes. Niemann-Pick disease type A 
(NPA) and B (NPB) are caused by a deficiency of the enzyme acid sphingomyelinase 
(SMase), which hydrolyses SM into ceramide and phosphorylcholine. NPA represents 
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a classical, acute neuropathic form of the disease, whereas NPB is a chronic form 
without nervous system involvement. NPC is clinically similar to NPA and NPB, but 
in NPC SMase is functional (Gieselmann, 1995). In NPC cells, cholesterol 
accumulates in late endocytic organelles due to impaired intracellular cholesterol 
trafficking. The late endosomal resident proteins Niemann-Pick protein 1 (NPC1) and 
HE1/NPC2 are known to be defective in NPC, but their functions are as yet unknown. 
NPC and mucolipidosis type IV (LaPlante et al., 2002) are unique among lysosomal 
storage diseases since in both the primary defect seems to be in transport and sorting 
along the endocytic pathway. In Chapter 4, NPC will be discussed in more detail. 
 
3.1 Accumulation of DRMs in lysosomal lipidoses 
The lipid composition of late endosomes and lysosomes is known to differ from that 
of early endosomes. Triglycerides, cholesterol esters and select phospholipids, 
including lysobisphosphatidic acid (LBPA), also called 
bis(monoacylglycerol)phosphate, are known to be enriched in late endosomal 
organelles (Brotherus and Renkonen, 1977; Kobayashi et al., 1998b; Wherrett and 
Huterer, 1972). How lipid rafts are handled and transported in the endocytic pathways 
is not yet understood in detail. It is thought that in normal cells there are fewer rafts in 
the late endosomes and lysosomes as compared with the PM where they are enriched. 
However, in pathological states such as lysosomal lipidoses, disturbances in 
membrane trafficking might lead to lysosomal raft accumulation (Simons and 
Gruenberg, 2000).  
In NPA and NPB SM accumulates in the late endosomes/lysosomes, whereas, 
in NPC the primary accumulating lipid is cholesterol. Both these raft components also 
accumulate in late endosomal compartments in other lipidoses. This observation led 
Simons and Gruenberg to hypothesise that, in lipid storage diseases involving raft 
lipids, the accumulation of one raft lipid, for example cholesterol or SM, would lead 
to the trapping of other raft lipids in late endosomes due to the physical interactions 
between them. This would further lead to impaired membrane dynamics and a “traffic 
jam” affecting both lipids and proteins (Liscum, 2000; Simons and Gruenberg, 2000). 
Experimental data from Pagano and coworkers support this hypothesis. By 
immunofluorescence studies, they observed that, in various lysosomal lipidoses, many 
fluorescent sphingolipid analogs and cholesterol accumulate in the late endosomal 
organelles (Pagano et al., 2000). It therefore seems that the interaction between 
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sphingolipids and cholesterol is critical for the regulation of endosomal membrane 
trafficking. A lysosomal membrane protein, acetyl-CoA:-glucosaminidase N-
acetyltransferase, which participates in the degradation of heparan sulfate, was 
recently shown to associate with DRM domains in preparations made from human 
placenta (Taute et al., 2002). This is the first report in which a lysosomal membrane 
protein has been shown to associate with rafts. It therefore seems likely that in normal 
cells, rafts exist in the late endosomal organelles. In pathological situations, e.g. in 
several lysosomal lipidoses, accumulation of one raft lipid could lead to the 
accumulation of other raft components and excessive raft formation. 
 
4. Niemann-Pick type C disease 
 
4.1 Clinical characteristics of NPC 
NPC is an autosomal recessively inherited neurodegenerative lysosomal storage 
disease. The age of onset can vary from early infancy to adulthood and the clinical 
manifestations are heterogeneous. The infantile form of NPC is rapidly progressive 
and the patients usually die before the age of two years of cholestasis and/or of liver 
failure. NPC patients with the “classic” form of the disease get their first symptoms in 
early childhood before school age, death occurring before the age of 20. Symptoms in 
the classic form include hepatosplenomegaly, ataxia, dystonia, seizures, vertical 
supranuclear gaze palsy (paralysis of down-gaze), and progressive dementia. The late 
onset form is a slowly progressive disease, the first symptoms occurring in 
adolescence or adulthood. NPC does not affect plasma lipoprotein levels or lead to 
vascular disease (Paterson, 2001). In the brain, NPC is associated with dendritic and 
axonal abnormalities, and progressive loss of neurons (Elleder et al., 1985; Higashi et 
al., 1993). Demyelination and formation of neurofibrillary tangles also occur (Auer et 
al., 1995; Love et al., 1995; Suzuki et al., 1995). 
NPC affects diverse ethnic groups. The prevalence of NPC has been estimated 
at approximately 1:150,000 in Europe but it may be under-diagnosed due to the 
clinical heterogeneity of the disease and to the limited availability of specific 
biochemical tests (Vanier and Suzuki, 1998). The frequency of NPC is much higher in 
geographically isolated populations like in Nova Scotia, where the incidence is 1% 
(Winsor and Welch, 1978). Individuals of Hispanic descent in parts of Colorado and 
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New Mexico, and the Israeli non-Jewish population also represent genetic isolates 
with a common founder (Millat et al., 1999; Zlotogora and Chemke, 1995). In Nova 
Scotia, a milder form of NPC was first erroneously considered to be a distinct class of 
the disease (Niemann-Pick type D), but later it was proved to be an allelic variant of 
NPC (Greer et al., 1998). 
 
4.2 Genetics of NPC 
In NPC, two genetic complementation groups, NPC1 and NPC2, have been identified 
by cell hybridisation studies and linkage analysis (Steinberg et al., 1994; Vanier et al., 
1996). In human the defective gene is NPC1 in 90-95% of the cases (Carstea et al., 
1997) and it has been localised to chromosome 18q11.2 (Carstea et al., 1993). 
HE1/NPC2 was recently identified as the protein mutated in the minor 
complementation group and was mapped to chromosome 14q24.3 (Naureckiene et al., 
2000). The complete genomic sequence of NPC1 is 57 kb (Bauer et al., 2002) and 
contains 25 exons (Morris et al., 1999) whereas HE1/NPC2 is about 13.5 kb long, 
containing 5 exons (Naureckiene et al., 2000). Mutational analysis has revealed over 
100 different alterations widely distributed throughout the NPC1 gene, many of which 
may represent polymorphisms (Bauer et al., 2002; Carstea et al., 1997; Garver and 
Heidenreich, 2002; Millat et al., 2001). The majority of the mutations are missense 
and nonsense mutations that alter the splicing of the mRNA. There are also several 
small insertions and deletions, some of which generate premature stop codons. One of 
the most prevalent mutations, the substitution I1061T, is a frequent mutant allele in 
patients of Western European descent and correlates with a classic juvenile phenotype 
of the disease (Millat et al., 1999). The majority of the NPC2 patients exhibit 
mutations leading to a rapid and severe clinical course. Recently, however, a novel 
phenotypic and genotypic NPC2 patient with an adult-onset disease characterised by 
diffuse cognitive impairment and focal frontal involvement was described 
(Klunemann et al., 2002). It is typical of NPC that the clinical phenotype cannot be 
predicted from the biochemical phenotype or the NPC1 mutation. Because the clinical 
symptoms and the cellular and biochemical phenotypes are similar in NPC1 and 
NPC2, these two gene products might function in tandem or sequentially (Carstea et 
al., 1997; Christomanou et al., 2000; Vanier et al., 1996). 
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NPC1 mutations have also been described in other species like in mice, cats and dogs 
(Kuwamura et al., 1993; Loftus et al., 1997; Munana et al., 1994). The phenotype in 
all there groups is very similar to human NPC disease.  
 
4.3 Biochemical characterisation of NPC 
In NPC the intracellular cholesterol homeostasis is severely impaired. In NPC cells 
LDL-cholesterol is normally taken into the cells by receptor-mediated endocytosis 
and cholesterol esters are hydrolysed in late endocytic organelles (Liscum and Faust, 
1987; Pentchev et al., 1985). However, owing to a transport block, the unesterified 
free cholesterol accumulates in large amounts in late endosomes/lysosomes (Fig. 3) 
and consequently cannot reach the regulatory sites of cellular cholesterol homeostasis 
(Fig. 4). Although late endosomes and lysosomes have been widely studied, it is 
difficult to draw the line between these organelle types because of the elusive 
boundary between them (Gruenberg, 2001). Thus, in this thesis the term late 
endosomes will be used to refer to these two organelle types.  
 
 
 
 
 
 
 
Figure 3. Filipin staining of human control fibroblasts (left) and NPC patient fibroblasts (right). Filipin 
is a fluorescent antibiotic that stains free cellular cholesterol. In NPC cells, cholesterol accumulates in 
the late endocytic organelles.  
 
Cholesterol accumulates not only in the late endosomes, but also in the trans-Golgi 
network of NPC cells (Blanchette-Mackie et al., 1988; Coxey et al., 1993). As a 
secondary effect, probably resulting from cholesterol accumulation, other lipids also 
accumulate in NPC cells. The accumulating lipid species vary between neuronal and 
nonneuronal tissues. Both in the spleen and the liver, there is an increase of SM as 
well as of cholesterol (Vanier, 1983). In the brain, there is a characteristic 
accumulation of different glycolipids, such as glucosylceramide, lactocylceramide, 
globoside, GM1, GM2 and GM3 (Taniguchi et al., 2001; Vanier, 1999). Recently, 
Karten and colleagues made the observation that the total cholesterol content in NPC- 
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and wild type (wt) neurons was the same, but the distribution differed. In the NPC 
neurons the total cholesterol mass in the cell bodies was larger than in normal cells, 
but, in the distal axons, was reduced (Karten et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Intracellular cholesterol homeostasis in NPC cells. LDL-cholesterol is normally taken into the 
cells by receptor-mediated endocytosis and cholesterol esters are hydrolysed in late endocytic 
organelles. However, due to mutations in the NPC1 or NPC2 genes the unesterified free cholesterol 
accumulates in late endosomes/lysosomes and its transport is defective to the PM and to the ER. 
 
 
Normal cells can respond to an increased cholesterol stimulus by down-regulating 
various genes involved in cholesterol homeostasis. When cultured in the presence of 
serum, they can down-regulate the synthesis of LDL receptors by lowering the 
receptor messenger RNA levels (Brown and Goldstein, 1975; Russell et al., 1983). 
LDL-cholesterol also affects cholesterol synthesis by suppressing the transcription of 
the HMG-CoA reductase gene (Luskey et al., 1983) and induces degradation of this 
cholesterol synthesising enzyme (Gil et al., 1985). In NPC cells, these regulatory 
mechanisms are impaired. LDL receptor activity or cholesterol synthesis cannot be 
down-regulated in spite of the increased intracellular cholesterol content (Liscum and 
Faust, 1987). Yet another homeostatic mechanism for regulating cellular free 
cholesterol is esterification in the ER by the enzyme Acyl-CoA:cholesterol 
acyltransferase (ACAT). In NPC cells, esterification is blocked or diminished because 
LDL-derived cholesterol is sequestered in the late endosomes and cannot reach the 
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ER (Liscum and Faust, 1987). It has been verified that the ACAT enzyme is 
functional in NPC cells (Pentchev et al., 1985). 
 
4.4 Diagnosis of NPC 
The diagnosis of NPC is confirmed by biochemical tests in cultured fibroblasts taken 
from a skin biopsy. The late endosomal cholesterol accumulation in NPC can be 
detected by fluorescence microscopy of cells stained with filipin, a fluorescent 
antibiotic that binds free cholesterol (Bornig and Geyer, 1974). When the patient cells 
are grown in medium containing LDL-cholesterol, a characteristic bright and intense, 
punctate, late endosomal staining pattern can be visualised (Fig. 3) (Blanchette-
Mackie et al., 1988).  
Another way to biochemically diagnose NPC is to measure the capacity of the 
cells to esterify cholesterol. The cells are fed with radioactively labelled fatty acid, 
e.g. [3H]oleate in the presense of LDL and the ability of the cells to incorporate 
labelled fatty acids into cholesterol esters is measured (Vanier et al., 1992). In the 
diagnosis, the most reliable results are obtained by using a combination of these two 
methods; staining the accumulated cellular cholesterol with filipin and demonstrating 
the impairment in cholesterol esterification (Vanier et al., 1991).  
A small percentage of NPC patients, “NPC variants”, present with clinical 
symptoms of NPC but show almost normal results in biochemical tests. In NPC 
variant cells, the filipin staining is less intense than in the phenotype of “classical” 
patients and cholesterol esterification may be normal or only moderately impaired 
(Vanier et al., 1991). These patients can be diagnosed by using a fluorescent 
sphingolipid analog, BODIPY-lactocylceramide (LacCer). The cells are challenged 
with an excess of LDL, followed by pulse-labelling with BODIPY-LacCer. In normal 
fibroblasts, the fluorescent lipid analog is internalised from the plasma membrane and 
targeted to the Golgi. In NPC variant cells, BODIPY-LacCer accumulates in the late 
endosomes analogously to the “classical” NPC disease and various other lysosomal 
lipidoses (Sun et al., 2001). 
 
4.5 The structure and subcellular localisation of NPC1 
The NPC1 cDNA sequence predicts a 1278 amino acid protein with 13 
transmembrane spans (Davies and Ioannou, 2000) and several domains conserved 
during evolution (Fig. 5). The predicted molecular weight of the NPC1 protein is 142 
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kDa. By Western blotting it was observed to be somewhat larger, ranging between 
165-190 kDa and was therefore suggested to be post-translationally modified (Patel et 
al., 1999). NPC1 was shown to be glycosylated, for treatment of cells with 
tunicamycin, an inhibitor of N-glycosylation, reduced the molecular weight to ~140 
kDa (Watari et al., 1999b). 
The amino-terminus of the NPC1 protein contains a signal peptide for ER 
targeting and a region termed the NPC domain, which is highly conserved between 
different species (amino acid residues 55-165 in human). The NPC domain contains 
eight conserved cysteines and a leucine zipper domain (residues 73-94) that has been 
proposed to mediate protein homo- and heterodimerization (Carstea et al., 1997). In 
the carboxy-terminus there is a di-leucine motif (LLNF) that has been shown to target 
proteins to the endosomes and to direct endocytosis from the plasma membrane 
(Fukuda et al., 1988; Petris and Mercer, 1999). Deletion of this signal was shown to 
target the NPC1 protein to the ER (Watari et al., 1999a) and not to the PM. It cannot 
be excluded that the deletion of the di-leucine motive possibly affects the protein 
folding and causes its retention in the ER.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A schematic illustration of the NPC1 protein.  
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Residues 615-797 in the transmembrane domains 3-7 constitute the sterol-sensing 
domain (SSD) (Carstea et al., 1997; Kuwabara and Labouesse, 2002). This region 
shows sequence similarity to key regulators of cholesterol metabolism. It was first 
identified in HMG-CoA reductase and SCAP (Brown and Goldstein, 1999; Goldstein 
and Brown, 1990). SSD-containing proteins also include Patched, Dispatched and 7-
dehydrocholesterol reductase (7DHCR). Patched and Dispatched are involved in the 
signalling cascade mediated by the cholesterol-modified morphogen Hedgehog 
(Burke et al., 1999; Ingham and McMahon, 2001) whereas 7DHCR is an enzyme that 
functions in cholesterol biosynthesis (Witsch-Baumgartner et al., 2001). 
The steady-state location of NPC1 has been determined by 
immunofluorescence and immunoelectron microscopy (immuno EM) (Frolov et al., 
2001; Garver et al., 2000; Patel et al., 1999). Based on immunofluorescence studies in 
normal cells, the NPC1 protein has been localized to late endocytic organelles that are 
positive for lysosome-associated membrane protein (Lamp)-2, lysosomal glycoprotein 
95 (lgp95), LBPA and the small GTPases Rab9 and Rab7, but negative for the cation-
independent mannose-6-phosphate receptor (MPR) and the early endosomal antigen 1 
(EEA-1). In normal cells, the NPC1 protein is thought to reside in structures that are 
distinct from the cholesterol-enriched organelles and only transiently interact with 
them (Higgins et al., 1999; Kobayashi et al., 1999; Liscum, 2000; Neufeld et al., 
1999; Patel et al., 1999; Watari et al., 1999a; Zhang et al., 2001b). By immuno EM, 
NPC1 was shown to colocalise with Lamp-2 in endosomal structures containing 
numerous intraluminal vesicles characteristic of multivesicular bodies (MVB). NPC1 
was seen at both the limiting membrane and at the membranes of the intraluminal 
vesicles (Frolov et al., 2001). Also Lamp-1 protein seems to be distributed in a similar 
fashion (Frolov et al., 2001; Möbius et al., 2003). Some proteins that are in transit 
through the late endosomes or destined to be degraded are known to be located within 
internal membranes (Kobayashi et al., 1998a).  
In NPC patient cells the endogenous NPC1 protein resides in multilamellar 
vesicles that contain cholesterol and LBPA, Lamp-2, CD63, lgp95, Rab9 and MPR 
(Kobayashi et al., 1999; Liscum, 2000). In NPC cells, a general impairment of 
membrane trafficking is thought to result in the distribution of MPR from the trans-
Golgi network to late endosomal compartments (Kobayashi et al., 1999). 
A cholesterol storage phenotype mimicking NPC can be induced by 
incubation of normal cells with various chemicals (Butler et al., 1992; Liscum and 
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Faust, 1989; Rodriguez-Lafrasse et al., 1990; Underwood et al., 1996). There are 
differences in the chemical structures of the compounds; progesterone is a steroid 
hormone, whereas U18666A and imipramine are hydrophobic amines. The 
mechanism by which they block cholesterol transport to the late endosomal organelles 
is not known. Incubation of cells with these agents causes the NPC1 protein to move 
from cholesterol-poor vesicles into cholesterol-containing Lamp-2 positive 
compartments (Neufeld et al., 1999). Moreover, upon incubation of cells with 
progesterone or U18666A, the level of the NPC1 protein is increased (Patel et al., 
1999). 
The functionality of the NPC1 protein can be studied by expressing it in 
NPC1-deficient cells exhibiting late endosomal cholesterol accumulation. The wt 
NPC1 protein is capable of clearing the cholesterol deposits from NPC1-deficient 
cells within the time frame of a transient transfection and thus of complementing the 
NPC phenotype (Watari et al., 1999a) as assessed by filipin staining (Vanier et al., 
1992). Chinese hamster ovary (CHO) mutant cells with a defective NPC1 protein are 
often used for these studies, because human NPC patient fibroblasts are difficult to 
transfect. The complementation assay is explained in greater detail in Results and 
discussion, Chapter 3.4. 
The importance of specific amino acids and of domains in the NPC1 protein 
have been analysed in several studies (Watari et al., 1999a; Watari et al., 1999b). 
Conserved cysteines in the NPC domain seem to be crucial for the correct location of 
the NPC1 protein, because, when mutated, the protein was unable to complement the 
NPC phenotype and was localised to the limiting membrane of the late endosomes. It 
was therefore suggested that, in order to facilitate cholesterol removal from 
endosomes, NPC1 protein has to localise in the cholesterol-enriched core of late 
endosomes (Watari et al., 1999a) 
Watari and colleagues also mutated four potential N-glycosylation sites in the 
N-terminal region of the NPC1 protein (Watari et al., 1999b). Proteins with only a 
single N-glycosylation site mutated were correctly located in the cells and could 
correct the NPC trafficking defect. When all four N-glycosylation sites were mutated, 
the protein was expressed at reduced levels and complemented only ~50% of the 
NPC1 cells compared with wt NPC1 (Watari et al., 1999b). NPC1 proteins harbouring 
mutations in the putative leucine zipper and SSD were also mistargeted to the surface 
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of the cholesterol-laden late endosomes and could not clear cholesterol accumulation 
(Watari et al., 1999b).  
 
4.6 The structure of HE1/NPC2 
Originally the HE1/NPC2 protein was identified as a cholesterol-binding glycoprotein 
that is secreted from the epididymis and is thus called human epididymis protein 1, 
HE1 (Kirchhoff et al., 1996; Okamura et al., 1999). In the year 2000, this protein was 
identified as the second gene causing Niemann-Pick type C disease, based on the 
following observations: Firstly, NPC cells belonging to the minor NPC2 
complementation group were observed to have undetectable levels of HE1 protein in 
Western blot analysis. Secondly, the HE1 protein was observed to comigrate with 
lysosome markers on sucrose gradients, and thirdly, also to bind the MPR 
(Naureckiene et al., 2000). Soluble lysosomal proteins are post-translationally 
modified with mannose-6-phosphate, which is recognised by MPRs, and which divert 
newly synthesised lysosomal proteins from the secretory pathway to the 
endolysosomal system (Griffiths et al., 1990). The final proof that HE1 is the 
defective protein in NPC2 was obtained when HE1 protein was introduced to NPC2 
patient cells, and observed to clear the late endosomal cholesterol accumulations. 
(Naureckiene et al., 2000). 
HE1/NPC2 is composed of 151 amino acids with a 19 amino acid long amino-
terminal signal peptide for secretion. The predicted molecular weight of HE1/NPC2 is 
14.3 kDa, but by immunoblot analysis two bands of ~16 and ~19 kDa can be detected, 
which may represent two differentially glycosylated forms of the protein. HE1/NPC2 
is ubiquitously expressed in human tissues and its orthologs from various species have 
conserved motifs, including a unique proline rich region with no close similarity to 
known mammalian proteins, six cysteine residues and three Asn-linked glycosylation 
sites (Nakamura et al., 2000). HE1/NPC2 also contains an ML domain (MD-2-related 
lipid-recognition) that is conserved between proteins that function in innate immunity 
and lipid metabolism (Inohara and Nunez, 2002).  
Based on evolutionary analysis, four regions predicted to be important for 
NPC2 function were found, and their specificity was studied, using site-directed 
mutagenesis. One region probably forms a hydrophobic pocket that binds cholesterol 
and another region was observed to be needed for the efficient secretion of NPC2 
protein from the cells (Ko et al., 2003). The 1.7 Å high-resolution crystal structure of 
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the NPC2 protein purified from bovine milk was recently resolved (Friedland et al., 
2003). The protein has an immunoglobulin-like -sandwich fold consisting of seven 
-strands arranged in two -sheets and containing three disulfide bonds. It has three 
small cavities, the overall shape of which matches well with the space-filling model of 
a cholesterol molecule. However, the cavities are too small and have to open up and 
two -sheets have to move apart and form a larger tunnel for the protein to bind 
cholesterol. The mutagenesis studies by Ko et al. also supported the proposed location 
of the sterol-binding site in NPC2.  
 
4.7 Regulation of cholesterol transport by NPC1 
In NPC cells the LDL-derived cholesterol is trapped in the late endosomal organelles 
due to NPC1 or NPC2 mutations. The cellular defects in NPC cells and the possible 
functions of NPC1 have been widely studied in different NPC1-deficient CHO cell 
lines (Cadigan et al., 1990; Millard et al., 2000). The Liscum group have isolated 
several cell lines defective in intracellular cholesterol metabolism by mutagenising 
CHO cells and selecting clones unable to mobilize LDL-derived cholesterol to the 
PM, using amphotericin B as a selection agent (Dahl et al., 1992). Some of these cell 
lines harbour a mutation in the NPC1 gene but in others the mutations are 
uncharacterised (Wojtanik and Liscum, 2003). 
The results concerning NPC1-mediated transport of LDL-derived cholesterol 
from late endosomes to the PM are contradictory. Cruz and colleagues studied this 
transport in NPC1 mutant CHO cell lines, CT60 and CT43 cells. The parental CHO 
cell line 25RA with which the NPC cells were compared harbours a gain-of-function 
mutation in SCAP, rendering the cells resistant to sterol-dependent transcriptional 
regulation. Transport from the late endosomes to the PM was studied by pulse-
labelling the cells with 3[H]cholesteryl linoleate (CL)-LDL and measuring the efflux 
of 3[H]cholesterol to 2-hydroxypropyl--cyclodextrin (CD). Surprisingly, the initial 
movement of cholesterol from the late endosomal compartments to the PM was found 
to be NPC1-independent, whereas after reaching the PM and subsequent 
internalisation, cholesterol trafficking required NPC1 (Cruz et al., 2000). In a recent 
study, Wojtanic and Liscum used essentially similar methodology to determine 
whether LDL-derived cholesterol en route to NPC1-containing organelles passes 
through the PM. However, they used cholesterol/CD complexes as efflux acceptors, 
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whereas Cruz et al. used only CD. They concluded that the arrival of LDL-derived 
cholesterol from the late endosomes to the PM was significantly delayed in NPC1 
cells and suggested that Cruz and colleagues may have detected an internal pool of 
cholesterol that is capable of being diverted to the PM by CD depletion (Wojtanik and 
Liscum, 2003). In fact, very recently Cruz and al. observed that indeed the longer 
extraction times with CD (over 30 minutes) they previously have used causes 
cholesterol in internal membrane compartments to redistibute to the PM where it 
becomes accessible to CD (Sugii et al., 2003). Therefore, these results are in accord 
with ours; in NPC cells the transport of LDL-derived cholesterol is defective from the 
endocytic compartments to the PM (see Results and discussion, 2.4). 
In addition to LDL-derived cholesterol, newly synthesised cholesterol is also 
likely to accumulate in the late endosomal compartments of NPC1 cells. 
Radioactively labelled endogenously synthesised cholesterol was found to accumulate 
in the late endocytic organelles after it had reached the PM (Cruz and Chang, 2000). 
The authors therefore concluded that separate pathways exist for post-plasma 
membrane trafficking of endogenous cholesterol and LDL-derived cholesterol to the 
internal compartments but the two pools have the same ultimate fate in NPC cells.  
The majority of the studies on cholesterol homeostasis in NPC have been 
performed in primary fibroblasts and CHO cells but not in neurons. However, the 
clinical hallmark of NPC is progressive neuronal deterioration. Thus, it is crucial to 
study cholesterol transport in neuronal cells also. Karten and colleagues observed that, 
in sympathetic neurons from NPC mice, the total cholesterol mass in the cell bodies 
was increased. By filipin staining the late endosomal compartments were seen to be 
filled with cholesterol, but the total cholesterol contents in NPC and wt neurons were 
similar. Cholesterol accumulated in the cell bodies but was decreased in the distal 
axons. The accumulated cholesterol was considered to originate from endogenous 
synthesis, since it had already accumulated before birth and did not diminish when the 
neurons were cultured without exogenous cholesterol. This strongly suggests that, in 
NPC1-deficient neurons, the transport of cholesterol from cell bodies to distal axons is 
impaired (Karten et al., 2002).  
In a further study, Karten and colleagues examined cholesterol trafficking and 
metabolism in sympathetic neurons. NPC1 was seen to be expressed in both cell 
bodies and distal axons in normal cells and the amount of LDL-derived cholesterol 
reaching the distal axons was the same in wt and in NPC1 neurons. However, the 
  29
transport of newly synthesised cholesterol was impaired (Karten et al., 2003). This 
indicates that, in addition to a defective endosomal cholesterol transport pathway, 
trafficking of endogenously synthesised cholesterol is also impaired in NPC cells. 
Lusa et al. have studied the transport of newly synthesised cholesterol in non-neuronal 
CT43 cells. In these cells the transport of endogenous cholesterol to the extracellular 
serum acceptors was already clearly impaired shortly after synthesis (S. Lusa and S. 
Heino, personal communication). 
The movement of the NPC1 protein and the dynamics of late endosomal 
compartments have been studied by live cell video microscopy. When the 
biosynthesis and trafficking of NPC1 protein fused to Green fluorescent protein (GFP) 
was studied, newly synthesised NPC1–GFP was seen to be transported from the ER 
through the Golgi to the late endosomes. NPC1-GFP containing late endosomes 
moved rapidly by a dynamic process involving tubulation and fission followed by fast 
retrograde and anterograde migration along microtubules. This movement of NPC1 
was dependent on an intact sterol-sensing domain and was retarded by an elevated 
endosomal cholesterol concentration in NPC cells (Zhang et al., 2001a). In another 
study an intact NPC1 protein was observed to be crucial in regulating both lipid 
sorting and tubular late endocytic trafficking (Ko et al., 2001). NPC1 containing 
organelles were shown to be associated with strands of the ER, but no contacts 
between NPC1 organelles and the PM were observed. Furthermore, Lebrand and 
colleagues reported that the microtubule-directed motility of late endosomal 
compartments was dependent on the membrane lipid composition and was paralysed 
in NPC cells with cholesterol accumulations. This movement was suggested to be 
regulated via the small GTPase Rab7 (Lebrand et al., 2002). 
The specific functional mechanism of NPC1 in cholesterol transport remains 
to be determined. It has been suggested to mediate transport of cholesterol-rich 
vesicles or to facilitate aqueous cholesterol diffusion (Liscum, 2000). In addition, a 
possible function of NPC1 as a transmembrane pump has been suggested (Davies et 
al., 2000). NPC1 was shown to contain regions homologous with the resistance-
nodulation-division (RND) family of prokaryotic permeases and to facilitate the 
transport of lipophilic molecules like fatty acids, but not cholesterol. 
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AIMS OF THE STUDY 
 
The aim of this study was to characterise the cellular defects underlying Niemann-
Pick type C disease by several different approaches. The detailed aims of the 
individual studies are listed below. 
 
In the first study the aims were to determine the lipid composition of normal and NPC 
fibroblasts by electrospray ionisation mass spectrometry and to analyse the plasma 
membrane lipid composition of samples incorporated into influenza and vesicular 
stomatitis viruses. In addition, we aimed to study the effects of acute cholesterol 
loading on the lipid composition of normal fibroblasts. 
 
The aim of the second study was to characterise the partitioning of LDL-derived 
cholesterol and NPC1 protein in membrane microdomains termed rafts in normal and 
NPC cells that accumulate cholesterol in late endosomal organelles. Further aims 
were to analyse the ultrastructure of late endocytic compartments of NPC cells and to 
measure the availability of LDL-cholesterol to extracellular acceptors in both normal 
and NPC cells.  
 
In the third study, the aim was to determine the mutations causing NPC disease in a 
Finnish patient and to characterise the subcellular location, biochemical behaviour and 
functional consequences of the mutant proteins. Further, we aimed to study the 
frequencies of the Finnish mutations in Finnish and Swedish populations, and to 
characterise the NPC2 protein in normal and patient cells. 
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METHODS 
 
 
The methods used in the original articles included in this thesis are summarised in the 
following table. The number of the original publication in which the method has been 
employed is indicated. 
 
Table 1. 
 
Method                                                                                                Publication 
Recombinant DNA techniques (cloning)                                                     III 
Site-directed mutagenesis                                                                             III 
DNA sequencing                                                                                           III 
Solid-phase minisequencing                                                                         III 
Conformation-sensitive gel electrophoresis (CSGE)                                    III 
Cell culture techniques                                                                             I, II, III 
Transient DNA transfection                                                                       II, III 
Generation of polyclonal antibodies                                                          II, III 
SDS-PAGE, immunoblotting, ECL (enhanced chemiluminiscence)      I, II, III 
Immunofluorescence microscopy                                                              II, III 
Immunoprecipitation                                                                                    III 
Electron microscopy                                                                                  I, II, III 
Metabolic labelling of cells                                                                          III 
Glycosidase digestion                                                                                   III 
Cell fractionation & detergent extraction                                                      II 
Virus infection & purification by gradient ultracentrifugation                      I 
Mass spectrometry                                                                                         I 
Lipid extraction                                                                                              I 
Protein mass quantification                                                                            I 
RNA isolation & Northern blot analysis                                                       III 
Surface biotinylation                                                                                     III 
Amino acid sequence comparison (ClustalW)                                              III 
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RESULTS AND DISCUSSION 
 
1. Mass spectrometric analysis of lipids in normal and NPC cells (I) 
 
1.1 Lipid composition of control and NPC human fibroblasts 
In Niemann-Pick Type C disease, the impaired cholesterol metabolism in the cells 
might lead to disturbances in raft-related cellular functions via altered membrane lipid 
composition. Raft-resident proteins are known to have important roles in various 
cellular functions such as cellular signalling (Magee et al., 2002). The lipid 
composition of NPC cells and especially of the plasma membrane has to be well 
studied in order to resolve the cellular and molecular defects underlying this disease.  
We quantitatively analysed the major lipid classes from control and NPC 
human primary fibroblasts. We chose a NPC1 patient cell line in which no 
immunoreactive NPC1 protein has been detected and that has been previously widely 
characterised (Lange et al., 2000). No clear differences between the major 
glycerophospholipid classes phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS) and sphingomyelin (SM) were observed. However, a 
clear difference in the cholesterol content was seen between control and NPC cells (I, 
Fig. 1). In the NPC cells there was about 2.5 times more cholesterol as in the to 
control fibroblasts. These data are in agreement with the cellular phenotype, where the 
cholesterol homeostasis is severely impaired and causes large amounts of cholesterol 
to accumulate in the late endosomes (Liscum and Faust, 1987; Paterson, 2001; 
Pentchev et al., 1985). SM and glycolipids are also known to accumulate in NPC cells 
(Vanier, 1983; Vanier, 1999), but apparently in smaller amounts than cholesterol, 
because we did not observe any significant changes in this study (I, Fig. 1). 
In addition to the major the phospholipid classes, the phospholipid molecular 
species were also analysed. In the control cells, remarkable differences in the acyl 
chain saturation were observed between the phospholipid classes, PE being the one 
with the most unsaturated acyl chains and PC having the highest degree of saturation 
(I, Fig. 2, Table 1). This agrees with previous results, PE being known to be rich in 
polyunsaturates and PC rich in monounsaturates (Mahadevappa and Holub, 1982; 
Murphy et al., 1993). 
Some differences between control and NPC cells were observed in the major 
phospholipid classes. The distribution of the PS and SM acyl chain classes were 
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similar, but clear differences could be observed in PC and PE acyl chain composition 
(I, Fig. 2, Table 1). In NPC there was a decrease in the mono- and diunsaturated 
species such as 34:1, 36:1 and 36:2, whereas some of the long-chain polyunsaturated 
species consisting of 36, 38 or 40 carbons and having 3-7 double bonds were 
increased.  
 
1.2 Plasma membrane lipid composition in control and NPC cells 
It is difficult to isolate and purify different cellular organelles totally devoid of 
contaminating material. To obtain relatively pure PM samples, we infected control 
and NPC fibroblasts with enveloped influenza and VSV viruses that both bud from 
the PM, influenza viruses from ordered, raft-like domains, and VSV from raft-poor 
domains (Keller and Simons, 1998; Scheiffele et al., 1999). Viruses were collected 
from the infection medium and concentrated by gradient centrifugation (I, Fig. 3).  
The lipid profiles of the influenza and VSV viruses were mostly similar (I, 
Fig. 4). Only slight differences in the amounts of the major phospholipid classes (PC, 
PE, PS, SM) or in their degree of saturation were observed. The only clear difference 
was that, in the influenza virus, glycosphingolipids were about 2-3 fold enriched both 
in the control and the NPC cells as compared with VSV. Glycosphingolipids are 
thought to be components of rafts, which is in agreement with the hypothesis that the 
influenza virus selects raft domains for budding (Scheiffele et al., 1999).  
Both viruses from NPC cells contained increased amounts of cholesterol (I, 
Fig. 4). In NPC influenza viruses the amount was 2 times higher than that in control 
cells whereas in VSV the increase was slightly smaller, about 1.4 fold. This indicates 
that the NPC PM domains used for virus budding are cholesterol enriched as 
compared with control cells. Previously, NPC cell plasma membranes have been 
considered to be cholesterol depleted in view of their resistance to the fungal sterol-
binding antibiotics filipin and amphotericin B (Dahl et al., 1992; Ohno et al., 1993). 
Decreased cholesterol concentrations in NPC cells were also observed when PM was 
isolated by sucrose gradient centrifugation (Koike et al., 1998). Lange and colleagues 
compared the PM cholesterol contents in control and NPC cells by measuring the 
extractability of radioactively labelled cholesterol to CD. They observed that the PM 
cholesterol content in two NPC patient cell lines were 20% greater than in the control 
cells (Lange et al., 2000). Recently, it was reported that NPC1-deficient mice are 
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resistant to Brucella abortus bacterial infection, which is thought to depend on PM 
cholesterol (Watarai et al., 2002).  
The variation in the results could be related to the different techniques used 
and difficulties in isolating pure PM by cell fractionation. In some of the studies, no 
PM isolation was performed, but instead the accessibility of cellular cholesterol to 
extracellular acceptors was measured. It is not certain that these chemicals react only 
with the PM cholesterol, but they may be internalised and thus the intracellular 
cholesterol content may influence the results. Extracellular acceptors might also react 
preferentially with some of the PM lipid domains. The viruses that we analysed are 
also likely to reorganise the PM structure and to choose specific membrane domains 
for exit. 
The PM phospholipid species in the viruses were analysed in detail (I, Fig. 5, 
6). There were no clear differences in the main phospholipid classes (PE, PS, PC, SM) 
between VSV and influenza viruses from control or NPC cells. However, interesting 
results were obtained when the acyl chain composition between viruses from NPC 
and control cells was analysed. Viruses that originated from NPC cells contained 
longer and more unsaturated acyl chains than those from control cells. The difference 
was largest in the PE molecules, a 30% increase in the polyunsaturated molecules 
with acyl chains typically composed of 38-40 carbon atoms. There was a 
corresponding reduction in the monounsaturated species typically with 34-36 carbons 
in the fatty acyl chains. A similar tendency was also observed for the PS and PC 
molecules from NPC cells. 
 
1.3 The effect of acute cholesterol loading on cellular lipid composition 
In NPC cells, a genetic defect leads to pathological accumulation of cellular 
cholesterol that in turn may lead to changes of phospholipid acyl chains. The 
mechanism behind this phenomenon is not known and therefore we studied if similar 
results are obtained when normal cells are loaded with cholesterol. This was done by 
using a CD carrier complexed with cholesterol in the presence or absence of an 
inhibitor of cholesterol esterification (ACAT inhibitor) PKF 058-035. An ACAT 
inhibitor was used to maximally load the cells with free cholesterol and inhibit 
cholesterol ester formation. After one hour of incubation with CD/cholesterol the 
cholesterol content of the cells had doubled (I, Fig. 7A). When the different 
phospholipid classes were analysed after 8 hours, an increase in PC unsaturation was 
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observed. After 24 hours of cholesterol loading clear differences in the PC, PE, and 
SM acyl chain saturation and length were observed (I, Fig. 7B-D). In PC and PE a 
reduction in the saturated or monounsaturated phospholipid species with a total of 32-
36 carbon atoms was observed whereas the polyunsaturated phospholipid species with 
36 or 38 carbons were increased. SM molecules containing 16 carbon atoms were 
decreased after CD loading, whereas longer 24 carbon chains with no or one double 
bond were increased. The same behaviour in the acyl chain saturation and length was 
observed in both the presence and absence of the cholesterol esterification inhibitor. 
These results clearly indicate that chronic cholesterol accumulation in NPC 
and acute cholesterol loading cause similar changes in the phospholipid acyl chains. 
SM in NPC cells was an exception. No clear differences in the SM acyl chain length 
or saturation between control and NPC cells (I, Fig. 2D) or plasma membranes (I, Fig. 
6C, D) were observed like those in CD loaded control cells. The reason for this is not 
known but an explanation might be that, in NPC cells, part of the SM is sequestered 
with cholesterol in the late endosomes and so is not available for the cellular 
machinery responding to the cholesterol excess elsewhere in the cell.  
SCD has been reported to be an important enzyme that affects cholesterol 
homeostasis, although the mechanisms interconnecting fatty acyl saturation and 
cholesterol levels are not yet known in detail. Diets high in cholesterol have been 
shown to induce SCD1 gene expression in mice (Kim et al., 2002; Landau et al., 
1997). Recently, the group of Tall (Sun et al., 2003) showed that overexpression of 
SCD modifies the PM organisation by increasing the amount of monounsaturated 
fatty acids (18:1) at the expense of the saturated ones (18:0) and decreases the number 
of PM DRM domains. In addition, cholesterol efflux to apoA-I was dramatically 
inhibited but the ABCA1-independent efflux to HDL2 was increased. In our study 
fatty acids other than those derived from stearate (18:0) were also increased after 
cholesterol loading and thus the upregulation of SCD alone cannot explain our 
findings. Excess cellular cholesterol may also induce the synthesis of other fatty acid 
desaturases that synthesise highly unsaturated fatty acids in the cells. Alternatively, 
the uptake of extracellular polyunsaturated fatty acids may be promoted. 
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2. The role of NPC1 in the recycling of LDL-cholesterol to the plasma membrane 
(II) 
 
2.1 Hydrolysis of [3H]CE-LDL in normal and NPC cells 
The hydrolysis kinetics of radioactively labelled [3H]CE-LDL in normal and NPC 
cells were measured. We used both wt CHO cells and CT60 cells that harbour an 
inactivating mutation in the NPC1 locus (Cadigan et al., 1990). In addition, control 
and NPC1 human primary fibroblasts were used. Before feeding the cells with LDL-
cholesterol, they were starved of sterol for three days in medium containing 
lipoprotein-deficient serum (LPDS) to maximise the uptake of radioactive LDL. 
[14C]cholesterol was present in the medium to equilibrium label the cellular 
cholesterol pool. An ACAT inhibitor was added to inhibit the re-esterification of 
hydrolysed free cholesterol. In the CHO cells, cellular hydrolysis of [3H]CE-LDL was 
measured after 30 minutes of labelling and chasing for from zero to two hours. In the 
case of human primary fibroblasts the cells were labelled for 18 hours followed by a 
chase for up to two hours. In the CHO cells, most (93%) of the internalised [3H]CE 
was hydrolysed after a chase of two hours (II, Fig. 1C), and in fibroblasts more than 
80% was hydrolysed during the same period. The hydrolysis of LDL-cholesterol was 
not significantly inhibited in NPC cells (II, Fig. 1C). These results are in accordance 
with previous observations that in NPC cells the uptake and hydrolysis of LDL-
derived cholesterol are normal (Liscum and Faust, 1987; Pentchev et al., 1985). 
 
2.2 Association of cholesterol with DRMs 
After measuring the hydrolysis of endocytosed LDL-derived [3H]cholesterol, we 
characterised its raft association and compared it with that of pre-existing cellular 
[14C]cholesterol in normal and NPC cells. In these experiments, two cells types were 
used: CHO cells and human primary fibroblasts. The raft association was studied in a 
Triton-Optiprep flotation gradient, based on the observation that raft microdomains 
are resistant to non-ionic detergents such TX-100 in cold (Simons and Ikonen, 1997). 
With this technique, the detergent-resistant, i.e. raft-associated, molecules float to the 
low-density top fractions in the density gradient, whereas the non-raft components are 
detergent-soluble and remain at the bottom.  
CHO and CT60 cells were pre-labelled with [14C]cholesterol for 72 hours to 
equilibrate the radioactive cholesterol with the cellular cholesterol pool. This was 
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followed by pulse-labelling with [3H]CE-LDL for 30 minutes. The detergent 
resistance of cholesterol was analysed directly after the pulse and with increasing 
chase times. Immediately after the pulse, the majority of the hydrolysed 
[3H]cholesterol in the wt CHO cells was detergent-soluble and only ~15% associated 
with DRMs (II, Fig. 2A). In the same cells, ~50% of pre-labelled cellular 
[14C]cholesterol was recovered in DRMs. Upon increasing the chase times, the 
detergent solubility of [14C]cholesterol in the wt CHO cells stayed similar, whereas 
the insolubility of [3H]cholesterol increased, with about 35% found in detergent-
resistant membranes after a chase of 6 hours.  
When the detergent-resistance of cholesterol in CT60 cells was studied, we 
observed that both [3H]cholesterol and [14C]cholesterol were more avidly associated 
with rafts at each time point analysed compared to wt CHO cells. In CT60 cells about 
70% of the pre-labelled cellular [14C]cholesterol was recovered in DRMs, while 50% 
was found there in wt CHO cells (II, Fig. 2B).  
Previously, the detergent solubility technique combined with gradient 
centrifugation has mostly been used for studying the raft association of proteins. Our 
data demonstrate that this is also a useful technique for studying different cellular 
cholesterol pools. According to our results, the majority of the hydrolysed LDL-
cholesterol initially partitions into non-raft domains, and is in a membrane 
environment clearly different from that of the pre-labelled cholesterol. After LDL-
derived cholesterol has been hydrolysed in late endosomal compartments, it is likely 
to be transported to the cell surface and to other intracellular compartments that 
contain more raft domains. Thus, with increasing chase times, the raft association of 
LDL-derived cholesterol increased and this was also correlated with increased 
accessibility of [3H]cholesterol to CD (see Results and discussion, Chapter 2.4).  
Hydrolysis of the CE in LDL particles occurs in the late endosomes and 
lysosomes, which are thought to be poor in lipid rafts. However, some late endosomal 
proteins and also cholesterol have recently been shown to be associated with DRMs. 
A lysosomal membrane protein, acetyl-CoA:-glucosaminidase N-acetyltransferase, 
was the first lysosomal membrane protein shown to be associated with rafts (Taute et 
al., 2002). The group of van der Goot studied the sorting and endocytosis of GPI-
anchored proteins in both CHO and baby hamster kidney (BHK) cells and observed 
that isolated late endosomes contain multiple detergent-resistant proteins, and part of 
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the cholesterol was also recovered in the same fractions (Fivaz et al., 2002). This is 
accordance with our results, that part of the cholesterol (~15%) derived from [3H]CE-
LDL becomes raft-associated soon after it starts hydrolysing. Thus, in normal cells 
there may be rafts in late endosomes, but in NPC cells the increased late endosomal 
cholesterol content may lead to imbalance in the ratio of raft to non-raft domains and 
thus lead to trafficking defects. 
 
2.3 Association of NPC1 with DRMs 
To study the raft association of the NPC1 protein, we used a similar Triton-Optiprep 
flotation gradient as was used to study the raft association of cholesterol. In addition, 
we used another method in which the cells are lysed in the cold in the presence of TX-
100 following centrifugation. With this method, the detergent-insoluble material is 
pelleted and the detergent-soluble components stay in the supernatant. When we 
analysed the detergent insolubility of endogenous NPC1 protein in control human 
fibroblasts, we found that the majority were associated with non-raft membranes (II, 
Fig. 4A). This agrees with the findings of Garver and colleagues (Garver et al., 2000). 
The effect of lipid loading on the raft association of NPC1 was studied by culturing 
the cells either in normal 10% serum containing medium or by depleting the cellular 
cholesterol by incubation in LPDS containing medium or by sterol loading the LPDS-
pretreated cells with 50 µg/ml of cholesterol and 10 µg/ml of progesterone. 
Progesterone is known to induce a morphological phenotype that mimics NPC disease 
with sequestering of cholesterol in the late endosomal organelles. Incubation of the 
cells in LPDS did not change the amount of raft-associated NPC1 protein, whereas 
cholesterol loading in the presence of progesterone increased it about four-fold (II, 
Fig. 4B). Two late endosomal resident membrane proteins, Lamp-2 and MPR, were 
studied as controls. Both were observed to be entirely in the detergent-soluble 
fractions in all the different conditions tested. 
Because the raft association of NPC1 seemed to be dependent on the cellular 
sterol status, we also wanted to study the behaviour of NPC1 protein in NPC lipidosis 
cells. In NPC patient fibroblasts (analysed in Blom et al. 2003/III) the raft association 
of NPC1 was increased compared to control fibroblasts (data not shown). We also 
studied the raft association of overexpressed wt NPC1 protein by transiently 
transfecting the NPC1 cDNA into wt CHO and CT60 cells (II, Fig. 4C). In the wt 
CHO cells, the majority of the NPC1 protein was in the non-raft fractions, whereas in 
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the CT60 cells the raft association of NPC1 was slightly increased. The results in the 
NPC patient fibroblasts and in the CT60 cells are in accordance with the increased raft 
association of NPC1 in normal cells after cholesterol load. 
Introduction of the functional NPC1 protein into NPC lipidosis cells is capable 
of unloading the late endosomal cholesterol deposits. We therefore analysed whether 
the raft-associated form of NPC1 protein represented the active form of the protein 
mediating cholesterol exit from the cells and whether this process was dependent on a 
functional sterol-sensing domain. We transfected wt CHO and CT60 cells with a non-
functional NPC1 that harbours a mutation, P691S, in the SSD. This mutant localises 
to the surface of cholesterol-laden late endosomes and cannot complement the NPC 
phenotype (Watari et al., 1999b). This mutant was equally raft-associated as the wt 
protein in both the CHO and CT60 cells (II, Fig. 4C) implicating that the raft 
association is not dependent on a functional NPC1 protein and an intact SSD.  
In the light of these results, the raft association of NPC1 seems to increase in 
non-physiological conditions, when there is a surplus of cholesterol in late 
endosomes. Moreover, in NPC cells the raft association of LDL-derived cholesterol is 
increased immediately after hydrolysis in the endocytic organelles. This suggests that 
there might indeed be raft formation in the late endosomal organelles in pathological 
situations such as NPC disease, as suggested by Simons and Gruenberg (Simons and 
Gruenberg, 2000). There could also be an alternative explanation for the increased raft 
association of NPC1 protein in NPC cells. The small portion of NPC1 protein that 
was seen to be raft-associated both in normal and NPC cells could represent a pool of 
the protein not located in late endosomes but in the organelles that contain more rafts 
than late endosomes. These could represent the PM, raft-enriched endosomes or the 
Golgi. In NPC cells, the proportion of the NPC1 protein with increased raft 
association might represent the mutant protein mistargeted to organelles containing 
more rafts. By surface biotinylation, we detected more NPC1 protein at the plasma 
membrane in NPC patient fibroblasts than in control cells (III, Fig. 3B, C), and by 
immunofluorescence studies it was also seen to be mislocalised to endocytic 
organelles (III, Fig. 5) that possibly contain raft lipids. 
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2.4 Cholesterol efflux to extracellular acceptors 
We studied whether the increased raft association of [3H]cholesterol in CT60 is 
correlated with the efflux to an extracellular acceptor, methyl--cyclodextrin. Wt 
CHO and CT60 cells were pre-labelled with [14C]cholesterol in LPDS containing 
medium for three days followed by labelling of [3H]CE-LDL cholesterol for 30 
minutes. The cells were chased for up to six hours, followed by incubation with 100 
mM CD for five minutes on ice. Methyl--cyclodextrin is a cyclic oligosaccharide 
that removes free sterols from the cellular membranes and has a high affinity for 
cholesterol (Irie et al., 1992; Ohtani et al., 1989). A short efflux time was used with a 
high CD concentration and the incubation was performed on ice to avoid 
internalisation of the CD molecules. This treatment extracted 17-20% of the pre-
labelled [14C]cholesterol from wt CHO cells (II, Fig. 5A).  
In wt CHO cells there was a clear increase in the cyclodextrin availability of 
free [3H]cholesterol between 0.5-2 h of chase (from ~10% to over 20%), suggesting 
the movement of hydrolysed [3H]cholesterol from intracellular sites to the cell surface 
(II, Fig. 5A). In CT60 cells the efflux of [3H]cholesterol to cyclodextrin was clearly 
inhibited; after two hours of chase, ~10% was effluxed from the cell surface. After six 
hours the amount was only marginally increased, suggesting that the movement of 
cholesterol from the late endosomes to the CD accessible sites of the plasma 
membrane is NPC1-dependent. The extractability of [14C]cholesterol was also lower 
in CT60 cells (13-15%) than in CHO cells (17-20%). This is in accord with Wojtanic 
and Liscum, who recently studied the transport of LDL-derived cholesterol to the PM 
and showed that this process is dependent on a functional NPC1 protein (Wojtanik 
and Liscum, 2003). 
We also studied the efflux of [14C]cholesterol to a physiological acceptor 
apolipoprotein A-I (apoA-I) in CHO cells (II, Fig. 5B). In CT60 cells, the efflux was 
clearly inhibited, being 10%, whereas in wt CHO cells it was 20%. It is possible to 
modify the raft lipid composition enzymatically with bacterial SMase, which catalyses 
the degradation of SM to ceramide and phosphocholine. With this treatment, 
cholesterol efflux to apoA-I has been shown to increase (Ito et al., 2000). After SMase 
treatment, the efflux from both wt CHO and CT60 cells was enhanced. However, the 
effect was more pronounced in the CHO cells. Thus, cholesterol efflux to apoA-I is 
defective in CT60 cells, even after SMase treatment which perturbs the raft integrity. 
  41
2.5 Morphological characterisation of U18666A-treated cells 
U18666A is an amphipathic molecule known to mimic the NPC phenotype by causing 
the accumulation of cholesterol in late endocytic organelles. We studied the 
morphology of U18666A-treated cells both by immunofluorescence microscopy and 
by electron microscopy. Wt CHO cells were incubated in the presence of 1 µg/ml of 
U18666A for up to 6 hours after which the cells were fixed and stained with filipin 
and anti-glycolipid antibodies. Already after 3 hours of incubation, bright, cholesterol-
filled punctate filipin-positive structures were observed (II, Fig. 3D). Anti-3’-LM1 
antibody staining revealed that glycolipids also accumulated in the same organelles 
(II, Fig. 3E). After 6 hours the intracellular staining became even more intense (II, 
Fig. 3G). Analysis at parallel time points by electron microscopy revealed the 
formation of multilamellar bodies that represented late endosomes or lysosomes, 
based on the accumulation of internalised BSA-gold after two hours of chase (II, Fig. 
3C, F, I). These lamellae accumulated free cholesterol, as indicated by a typical 
undulating membrane deformation caused by the filipin treatment (II, Fig. 3J) 
(Blanchette-Machie and Pentchev, 1998). 
 
3. Characterisation of the trafficking defect in Finnish NPC cells (III) 
 
In this study we characterised the genetics and cellular defects in a Finnish patient 
with NPC. This is the first case of NPC that has been diagnosed in Finland. At the age 
of one year, the patient was investigated on account of recurrent respiratory infections 
and was noted to have splenomegaly. After six months, retarded motor and 
intellectual development, brain atrophy, and liver and spleen enlargement were 
diagnosed. At the age of two years the patient was ataxic and his lower extremities 
were spastic. In electromyography, neuropathic changes were observed. In the bone 
marrow, liver and lungs there were large macrophages with foamy cytoplasm that are 
typical of NPC. By electron microscopy, intralysosomal lamellar dark bodies were 
observed. The diagnosis of NPC was confirmed from cultured skin fibroblasts in the 
laboratory of Dr. Marie Vanier (Univ. of Lyon, France), with filipin staining and 
demonstration of impaired cholesterol esterification (see Chapter 4.4). According to 
the classification by Vanier and Suzuki, the patient represents a severe infantile form 
of NPC with onset of the first neurological symptoms at age <2 years (Vanier, 1996). 
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A case report of the patient has been published in a Finnish medical journal (Ukkonen 
et al., 1995). 
 
3.1 NPC1 mutation analysis 
We screened for mutations causing an infantile form of NPC in the Finnish patient by 
conformation sensitive gel electrophoresis (CSGE). Three different mutations in the 
NPC1 gene we identified; two point mutations that cause amino acid substitutions 
C113R and P237S in the NPC1 protein, and a four-nucleotide deletion in the carboxy 
terminus (delC) (III, Fig. 1). Both point mutations were localised to the large amino-
terminal loop of NPC1 that is thought to be exposed in the lumen of late endosomes 
(Davies and Ioannou, 2000). C113R resides in the NPC domain (amino acids 55-165 
in human NPC1) that is conserved between different species. P237S is also localised 
in the N-terminus outside the NPC domain close to C113R. DelC causes a frame shift 
in the nucleotide sequence, leading to the incorporation of 36 novel amino acids and a 
premature stop codon that truncates the C-terminus of the protein. To extensively 
characterise the cellular, biochemical, and functional characteristics of the individual 
mutations, we created three individual DNA constructs (NPC1-C113R, NPC1-P237S 
and NPC1-delC) by site-directed mutagenesis, each harbouring one of the mutations, 
and expressed them separately in cells.  
 
3.2 Characterization of the NPC1 mutant protein in the patient fibroblasts 
By immunofluorescence microscopy we compared the characteristics of the NPC1 
protein in control and NPC patient fibroblasts (III, Fig. 2A). In control cells the NPC1 
protein colocalised extensively with the late endosomal marker Lamp-1 as reported 
earlier (Frolov et al., 2001; Neufeld et al., 1999). In NPC patient cells the staining was 
more diffuse, reaching to the cell periphery and even visualising the PM. In addition, 
there was punctate staining colocalising with Lamp-1 positive structures and 
concentrating in the perinuclear area. With the fluorescent cholesterol-binding agent 
filipin free cholesterol was seen to accumulate in the late endocytic organelles (Fig. 
2B). The glycolipid 3’-LM1 also accumulated in the same structures. As judged by 
filipin staining the cholesterol accumulation in these patient cells was more 
pronounced than in several other NPC cell lines we have studied (unpublished 
observation).  
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We characterised the endosomal morphology in the NPC fibroblasts at the 
ultrastructural level by electron microscopy (III, Fig. 2C-E). Cryofixation with freeze-
substitution was used, because this technique preserves the lipid-enriched structures 
more reliably than traditional methods (Hess and Siljander, 2001). Late endosomal 
compartments in the NPC cells were composed of a granular matrix and multi-
lamellar/vesicular structures that concentrated around the nucleus. Structures of these 
kinds have been seen previously in NPC cells (Frolov et al., 2001; Garver et al., 
2000). By immuno-electron microscopy, the mutant NPC1 protein and glycolipid 3’-
LM1 were seen to localise in the same structures in NPC cells (III, Fig. 2E). On the 
basis of the morphological data, we concluded that in the Finnish patient cells some of 
the NPC1 protein is capable of targeting to correct cellular destinations but a fraction 
of it mislocalises.  
The endogenous NPC1 protein was compared in control and NPC patient cells 
by Western blotting (III, Fig. 3A). No clear differences either in the size or the 
amount of the protein were observed. Surface biotinylation revealed that there is about 
twice as much NPC1 protein on the cell surface of the patient cells as compared to 
control cells (III, Fig. 3B, C). This suits well with our immunofluorescence data, 
which showed altered NPC1 protein distribution in the patient cells. 
 
3.3 Characterization of individual mutations using transient overexpression 
By individually expressing the different mutation constructs generated in the NPC1 
cDNA, we studied the stability, maturation, subcellular localisation and functionality 
of the mutant proteins in COS-1 and CHO cells.  
The stability of the wt and the mutant NPC1 proteins was compared in COS-1 
cells by metabolically labelling the overexpressed proteins with [35S]Methionine for 1 
hour and chasing for 4 hours. The cells were lysed and the proteins were 
immunoprecipitated with anti-NPC1 antiserum, followed by separation by SDS-
PAGE and visualisation by autoradiography (III, Fig. 4A). The NPC1-wt, NPC1-
C113R and NPC1-P237S were expressed at similar levels immediately after the pulse 
and after 4 hours of chase. The NPC1-delC mutation, however, was unstable with 
clearly smaller amounts of immunoprecipitated NPC1 protein present after 1 hour of 
chase, and progressively less after longer chase times. 
Because the carboxy terminal deletion resulted in an unstable protein, we 
studied the subcellular localisation of the other mutants (NPC1-C113R and NPC1-
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P237S) in detail by immunofluorescence microscopy. NPC1-wt is known to localise 
to the late endosomal organelles, which are positive for Lamp-1 and the small GTPase 
Rab7 (Kobayashi et al., 1999; Liscum, 2000). In COS-1 cells, the NPC1-P237S 
mutant colocalised with the late endosomal marker Lamp-1, as did the NPC1-wt 
protein (III, Fig. 4B). Similarly, the P237S mutant was found to overlap with Rab7 in 
CHO cells (III, Fig. 4C). On the other hand, the C113R mutant was seen to partially 
colocalise with the late endosomal markers, while most of the protein was found in 
Lamp-1-negative punctate structures and along the nuclear envelope (III, Fig. 4B, C). 
To further analyse the subcellular localization of NPC1-C113R, double 
immunostainings were performed. C113R colocalised extensively with a protein 
resident in the endoplasmic reticulum, phosphate disulfide isomerase (PDI) (III, Fig. 
4B) but it did not colocalise with fluorescent transferrin (III, Fig. 5), a classical 
marker for the endocytic recycling compartments. It partially overlapped with 
fluorescent dextran, which is a fluid phase endocytic tracer and also with EEA-1 (III, 
Fig. 5). When the intracellular versus PM localisation of NPC1-wt and NPC1-C113R 
was studied by surface biotinylation and Western blotting, we found that the NPC1-
C113R was localised to the PM more avidly than the NPC1-wt (III, Fig. 4E).  
The biosynthetic maturation of NPC1-C113R was studied by pulse-labelling 
cellular proteins with [35S]Methionine and chasing for 4 hours. This was followed by 
immunoprecipitation with anti-NPC1 antibodies and digestion with endoglycosidase 
H (Endo H) (III, Fig. 4D). This enzyme cleaves high mannose and some hybrid 
oligosaccharides from N-linked glycoproteins in the ER. When the oligosaccharides 
are further processed in the Golgi apparatus they become Endo H resistant. Both the 
NPC1-wt and NPC1-C113R were relatively slowly transported from the ER, as 
judged by the gradual acquisition of Endo H resistance within the course of 4 hours. 
NPC1-C113R developed slightly delayed Endo H resistance as compared with the 
NPC1-wt, indicating that the point mutation possibly affects the folding of the mutant 
protein and partly restrains the exit from the ER. We therefore concluded that NPC1-
P237S localises correctly in the late endosomes but NPC1-C113R becomes 
mislocalised into several structures, including the ER, plasma membrane, and earlier 
endocytic organelles. 
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3.4 Functionality of the individual mutant proteins, as assessed by 
complementation assay 
The precise role of the NPC1 protein is not known but its functionality can be studied 
by an assay that is based on the capability of the NPC1 protein to unload the late 
endosomal cholesterol from NPC1 cells. We transfected the NPC1-wt, NPC1-C113R, 
NPC1-P237S and NPC1-delC to M12 cells that are NPC1-defective CHO cells with 
late endosomal cholesterol accumulation (Millard et al., 2000). At three days post-
transfection the cells were fixed, and the capability of wt and mutant proteins to 
complement the NPC1 phenotype was assessed by filipin staining of cells stained with 
anti-NPC1 antibodies (III, Fig. 6A). The cells were scored into three categories (Fig. 
6) based on the following criteria: In category 1 “not complemented” were the cells 
that had no decrease in filipin staining in the NPC1-positive organelles. In the 
category 2 “partially complemented” 50-80% of the NPC1-positive organelles lacked 
filipin-positive storage material. In the category 3, “fully complemented” over 80% of 
the NPC1-positive organelles lacked filipin-positive storage material.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The cells were scored into three categories based on the ability of the NPC1 protein to unload 
the late endosomal cholesterol accumulation in NPC1-deficient M12 cells. The cells were fixed at 3 
days post-transfection, stained with anti-NPC1 antibodies and filipin, and viewed with an 
immunofluorescence microscope. 
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200 cells per construct were scored except for 20 cells per delC, because, owing to the 
instability of this protein, it was very difficult to find cells expressing NPC1. No 
significant difference between NPC1-wt and NPC1-P237S could be observed; nearly 
all of the cells expressing these proteins belonged to the second or third category and 
were capable of complementing M12 cells (III, Fig. 6B). NPC1-C113R and NPC1-
delC were both clearly defective in unloading the cholesterol accumulations from 
M12 cells and thus all cells expressing these two mutants belonged to the category 
“not complemented”. 
 
3.5 NPC2 protein in control and NPC1 patient cells 
NPC2 is a small, soluble cholesterol-binding protein that is defective in about 5 % of 
the NPC patients. In NPC1 and NPC2 patients, the clinical, cellular and biochemical 
phenotypes are very similar. Considering the postulated idea that NPC1 and NPC2 
proteins may function in tandem or sequentially (Carstea et al., 1997; Christomanou et 
al., 2000; Vanier et al., 1996), we compared the NPC2 protein and messenger RNA 
levels in the control and NPC1 patient fibroblasts. In addition, the subcellular 
localisation of the endogenous NPC2 protein was analysed by fluorescence 
microscopy.  
Cell lysates from control and NPC1 patient fibroblasts were separated by SDS-
PAGE, followed by Western blotting and incubation with rabbit polyclonal antibodies 
against the amino acids Glu20-Leu151 of the human NPC2 protein. These antibodies 
recognised a typical duplet of bands between 20 and 25 kDa. In NPC patient cells the 
amount of NPC2 protein was about 1.5 times higher than in control cells (III, Fig. 9A, 
B). Also the messenger RNA levels were increased in NPC cells, as shown by 
Northern blot analysis (III, Fig. 9C). This may represent a compensatory upregulation 
of NPC2 in the NPC1-deficient cells. 
Immunofluorescence microscopy of control fibroblasts with anti-NPC2 
antibodies showed slight variation in the staining pattern from cell to cell (III, Fig. 8B, 
C). In some cells a punctate staining pattern extending towards the cell periphery 
prevailed, whereas in others a punctate and/or tubular perinuclear staining pattern was 
visualised most intensively. By double-immunostaining, the punctate NPC2-positive 
organelles were found to colocalise with Lamp-1 (III, Fig. 8B), while the tubular 
perinuclear structures colocalised with the trans-Golgi marker, gamma-adaptin (III, 
Fig. 8C). In addition, some punctate anti-NPC2 staining was also visualised in cellular 
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extensions (III, Fig. 9D). These peripheral organelles were negative for Lamp-1. In 
contrast, in NPC1 patient cells no perinuclear NPC2 staining (III, Fig. 9D) 
colocalising with gamma-adaptin was observed. A majority of the NPC2 
immunoreactivity was seen in punctate, Lamp-1 positive structures that also contained 
cholesterol. Interestingly, the mannose-6-phosphate receptor was partially seen to be 
redistributed from its predominant location in the trans-Golgi area to the late 
endosomes. In NPC the defects of cholesterol transport seem to be linked to general 
disturbances in membrane trafficking. This has already previously been shown by the 
accumulation of various lipids and fluid phase markers in the late endosomal 
compartments (Neufeld et al., 1999; Taniguchi et al., 2001; Vanier, 1999). The 
imbalance in membrane trafficking due to lysosomal cholesterol egress might lead to 
missorting of MPRs and this might in turn cause the mistargeting of the NPC2 
protein. Alternatively, the mistargeting of NPC2 could be a direct effect from altered 
interaction between NPC1 and NPC2 proteins due to the NPC1 mutations. 
 
3.6 The population frequency and evolutionary conservation of the identified 
NPC1 mutations 
On the basis of our biochemical and morphological data, NPC1-C113R and NPC1-
delC are the disease-causing mutations in the Finnish NPC patient. Because no 
differences between NPC1-wt and NPC1-P237S were observed, NPC1-P237S is 
likely to be a polymorphism. To study whether the base changes present in the Finnish 
patient occur in the normal population, we analysed pooled DNA samples from 
Finnish and Swedish populations by solid-phase minisequencing (III, Table 1). With 
this method it is possible to quantitatively detect the presence of a mutant allele as 
1% of a pooled DNA sample (Olsson et al., 2000). The proportion of the mutant 
allele in a pooled sample corresponds directly to its frequency in the population from 
which the pooled sample is derived. C113R and delC were not prevalent (over 1%) in 
either population, i.e. the signal ratios measured were indistinguishable from the 
corresponding ratios in a control individual homozygous for wt NPC1. In contrast, 
P237S occurred with a frequency of 4,3-4,7% in both populations. In previous studies, 
the amino acid substitution P237S has been found in several NPC patients. It was 
reported as a disease-causing mutation not occurring in over 100 unaffected Japanese 
subjects (Yamamoto et al., 2000) or in 95 French subjects (Millat et al., 2001). 
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However, in another study it was suggested to represent a benign polymorphism based 
on its identification in ~2% in the US population (in 2 of 98 chromosomes) (Sun et 
al., 2001). Based on this study and also our results, P237S is likely to represent a 
polymorphism. However, it cannot be ruled out that it may have some modulatory 
role in cellular cholesterol homeostasis, although it functioned as the wt NPC1 in the 
complementation assay. 
The evolutionary conservation of the substituted amino acids cysteine C113 
and proline P237 was studied in NPC orthologs (III, Fig. 7). C113 of human NPC1 
was conserved between all the species analysed and P237 was conserved in all the 
mammalian species analysed. Both mutations are located within highly conserved 
regions in the polypeptide chains. However, no three-dimensional model of the NPC1 
protein exists, because large multimembrane span proteins are extremely difficult to 
crystallize. Therefore it is not known where, in the three-dimensional structure, these 
two residues are located or how these amino acid substitutions possibly change the 
structure and the function of the NPC1 protein.  
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CONCLUSIONS AND FUTURE PROSPECTS 
 
This doctoral thesis consists of articles in which we have extensively characterised the 
cellular defects in NPC. It is important to thoroughly dissect the normal function of 
the NPC1 and NPC2 proteins and to investigate the interacting cellular machinery in 
order to find a cure for this fatal disease. 
By mass spectrometry, we quantitatively determined the lipid molecular 
species in human control and NPC patient fibroblasts and in their plasma membrane 
incorporated into enveloped viruses (influenza and VSV). Glycolipids were seen to be 
enriched in domains through which influenza virus buds. The cholesterol content in 
both viruses derived from NPC cells was higher than in those from control cells. An 
important observation was that both the chronic cholesterol load in NPC cells and the 
acute load chemically induced by incubation of cells with CD/cholesterol complexes 
were accompanied by an increase in the polyunsaturated species of the major 
membrane phospholipids. This may be an important adaptive mechanism to increase 
the fluidity in cellular membranes against cholesterol excess. 
The raft association of cholesterol and NPC1 protein was studied in normal 
and NPC cells. In normal cells, most of the of [3H]cholesterol released from 
[3H]cholesteryl ester-LDL associated with detergent-soluble membranes soon after its 
hydrolysis, and was rapidly transported to the plasma membrane, becoming 
increasingly detergent-insoluble with time. In NPC cells, the raft association of LDL-
derived cholesterol was enhanced compared to normal cells and its transport to the 
plasma membrane was inhibited, as measured by accessibility to cyclodextrin. In 
normal cells, the NPC1 protein was mostly recovered in detergent-soluble membranes 
and its raft association was increased by late endosomal cholesterol loading. In 
addition to cholesterol, sphingolipids also accumulated in NPC cells in structures that 
consisted of multilamellar bodies in late endocytic organelles. Our results thus suggest 
that late endocytic organelles are normally raft-poor, but in NPC there is 
overcrowding of raft lipids in the degradative compartments. In normal cells, 
endocytosed LDL-cholesterol is efficiently recycled to the plasma membrane in an 
NPC1-dependent process. This is an important finding since little is known about the 
specific transport routes NPC proteins are involved in. 
We analysed the mutations causing a rapidly progressing infantile form of 
NPC. Two N-terminal point mutations (C113R, P237S) and a C-terminal four-
  50
nucleotide deletion leading to a frameshift and a premature stop codon (delC) in the 
NPC1 gene were identified. When the mutations were individually expressed in cells, 
the delC was observed to produce an unstable protein. NPC1-wt and NPC1-P237S 
were localised to late endosomes, but NPC1-C113R mislocalised to the ER, cell 
surface and Rab7-negative endosomes. NPC1-P237S, like NPC1-wt, was able to clear 
the late endosomal cholesterol accumulations from NPC cells, whereas NPC1-C113R 
and delC were unable to do this. When the frequencies of the mutations in the Finnish 
and Swedish populations were studied, no C113R or delC mutations were found, 
whereas ~5% of the chromosomes carried the P237S allele. Our results thus suggested 
that P237S is a prevalent NPC1 polymorphism in the Finnish and Swedish 
populations. When the NPC2 protein was studied in NPC1 patient cells we found it to 
be upregulated and to accumulate in the cholesterol storing late endosomes. This 
suggests that NPC1 governs the endocytic transport of NPC2.  
At present, the two defective genes underlying Niemann-Pick type C disease 
have been characterised but much still remains to be learned about the function of the 
NPC proteins. The ultimate goal is to resolve the molecular mechanisms by which 
NPC1 and NPC2 carry out their functions. Also the interaction partners of these 
proteins are yet to be identified as well as the whole cascade in which the NPC 
proteins are involved. Most of the studies on cholesterol homeostasis in NPC cells 
have been performed in cultured fibroblasts. However, as NPC leads to progressive 
neurodegeneration it is crucial to study this cholesterol transport machinery in 
neuronal cells. Also the relationship between the NPC proteins and the cellular sterol 
regulatory machinery has to be addressed. It will be interesting to know if NPC 
proteins are regulated by similar mechanisms as are the proteins SCAP and HMG-
CoA reductase that also have a sterol sensing domain like NPC1.  
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